KOMIPHARM INTERNATIONAL CO., LTD.
Biopharmaceutical company developing products for animal and human health.
041960 | KO
Overview
Corporate Details
- ISIN(s):
- KR7041960006
- LEI:
- Country:
- South Korea
- Address:
- 경기도 시흥시 경제로 17, 시흥시
- Website:
- https://komipharm.co.kr/en/
- Sector:
- Manufacturing
Description
Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-03-10 00:00 |
의결권대리행사권유참고서류
|
Korean | 143.8 KB | ||
| 2021-03-04 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 11.3 KB | ||
| 2021-03-02 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 9.3 KB | ||
| 2021-02-25 00:00 |
주주총회소집결의
|
Korean | 12.7 KB | ||
| 2021-02-19 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 11.3 KB | ||
| 2020-12-16 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2020-12-15 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 129.2 KB | ||
| 2020-12-10 00:00 |
투자판단관련주요경영사항(지속적인 암 통증 환자에서 PAX-1의 진통 활동을 평가하기 위한 탐색적, 무작위, 이중 맹검, 병렬 그룹, 위약 대조…
|
Korean | 13.5 KB | ||
| 2020-12-04 00:00 |
투자판단관련주요경영사항(새롭게 진단된 교모세포종 및 재발성 교모세포종 환자에서 PAX-1의 안전성 및 유효성 평가를 위한 식품의약품안전처(MF…
|
Korean | 13.1 KB | ||
| 2020-12-04 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 10.9 KB | ||
| 2020-11-16 00:00 |
분기보고서 (2020.09)
|
Korean | 1.5 MB | ||
| 2020-10-14 00:00 |
투자판단관련주요경영사항(코로나-19 바이러스로 인한 폐렴환자에서 PAX-1의 안전성 및 유효성 평가를 위한 스페인의약품위생제품청(AEMPS) …
|
Korean | 9.9 KB | ||
| 2020-10-13 00:00 |
투자판단관련주요경영사항(지속적인 암 통증 환자에서 PAX-1의 진통 활동을 평가하기 위한 탐색적, 무작위, 이중 맹검, 병렬 그룹, 위약 대조…
|
Korean | 12.9 KB | ||
| 2020-09-18 00:00 |
투자판단관련주요경영사항(교모세포종 및 재발성 교모세포종 환자에서 PAX-1의 안전성 및 유효성 평가를 위한 식품의약품안전처(MFDS) 임상 2…
|
Korean | 13.0 KB | ||
| 2020-09-08 00:00 |
투자판단관련주요경영사항(코로나-19 바이러스로 인한 폐렴환자에서 PAX-1의 안전성 유효성 평가를 위한 이탈리아의약품청(AIFA) 임상2/3…
|
Korean | 10.9 KB |
Automate Your Workflow. Get a real-time feed of all KOMIPHARM INTERNATIONAL CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for KOMIPHARM INTERNATIONAL CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for KOMIPHARM INTERNATIONAL CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
